Angiotensin II type 1 receptor antagonists prevent glucose‐induced increases in islet blood flow in rats

References

• Islets of Langerhans. Morphology and postnatal growth. Joslin's diabetes mellitus, 14th edn, S Bonner‐Weir, C. R Kahn, G. R Weir, G. L King, A. M Jacobson, A. C Moses, R. J Smith. Lippincott Williams and Wilkins, Philadelphia 2005; 41–52
   Google Scholar
• Jansson L. The regulation of pancreatic islet blood flow. Diabet Metab Rev 1994; 10: 407–16
   PubMed Web of Science ®Google Scholar
• Atef N., Ktorza A., Picon L., Penicaud L. Increased islet blood flow in obese rats: role of the autonomic nervous system. Am J Physiol 1992; 262: E736–40
   Google Scholar
• Svensson A. M., Abdel‐Halim S. M., Efendic S., Jansson L., Ostenson C. G. Pancreatic and islet blood flow in F1‐hybrids of the non‐insulin‐dependent diabetic GK‐Wistar rat. Eur J Endocrinol 1994; 130: 612–16
   PubMedGoogle Scholar
• Iwase M., Sandler S., Carlsson P. O., Hellerstrom C., Jansson L. The pancreatic islets in spontaneously hypertensive rats: islet blood flow and insulin production. Eur J Endocrinol 2001; 144: 169–78
   PubMedGoogle Scholar
• Jansson L., Andersson A., Bodin B., Kallskog O. Pancreatic islet blood flow during euglycaemic, hyperinsulinaemic clamp in anaesthetized rats. Acta Physiol 2007; 189: 319–24
   PubMedGoogle Scholar
• Jansson L. Effects of the biguanide metformin on splanchnic blood flow in rats: preferential and dose‐dependent increase in islet blood flow. Pharmacology 1995; 51: 43–7
   PubMed Web of Science ®Google Scholar
• Iwase M., Nakamura U., Uchizono Y., Nohara S., Sasaki N., Sonoki K., et al. Nateglinide, a non‐sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats. Eur J Pharmacol 2005; 518: 243–50
   PubMedGoogle Scholar
• Carlsson P. O., Berne C., Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127–33
   PubMed Web of Science ®Google Scholar
• Hypertension in Diabetic Study (HDS). Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309–17
   PubMedGoogle Scholar
• Ferranninni E., Buzzigoli G., Bonadonna R., Giorico M. A., Oleggini M., Graziadei L., et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–7
   PubMedGoogle Scholar
• Elliott W. J., Meyer P. M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta‐analysis. Lancet 2007; 369: 201–7
   PubMed Web of Science ®Google Scholar
• Cooper S. A., Whaley‐Connell A., Habibi J., Wei Y., Lastra G., Manrique C., et al. Renin‐angiotensin‐aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol 2007; 293: H2009–23
   PubMed Web of Science ®Google Scholar
• Leung P. S. The physiology of a local renin‐angiotensin system in the pancreas. J Physiol 2007; 580: 31–7
   PubMedGoogle Scholar
• Tikellis C., Cooper M. E., Thomas M. C. Role of the renin‐angiotensin system in the endocrine pancreas: implications for the development of diabetes. Inter J Biochem Cell Biol 2006; 38: 737–51
   PubMed Web of Science ®Google Scholar
• Ko S. H., Kwon H. S., Kim S. R., Moon S. D., Ahn Y. B., Song K. H., et al. Ramipril treatment suppresses islet fibrosis in Otsuka Long‐Evans Tokushima fatty rats. Biochem Biophys Res Commun 2004; 316: 114–22
   PubMedGoogle Scholar
• Tikellis C., Wookey P. J., Candido R., Andrikopoulos S., Thomas M. C., Cooper M. E. Improved islet morphology after blockade of the renin‐angiotensin system in the ZDF rat. Diabetes 2004; 53: 989–97
   PubMed Web of Science ®Google Scholar
• Chu K. Y., Lau T., Carlsson P. O., Leung P. S. Angiotensin II type 1 receptor blockade improves beta‐cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006; 55: 367–74
   PubMed Web of Science ®Google Scholar
• Shao J., Iwashita N., Ikeda F., Ogihara T., Uchida T., Shimizu T., et al. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta‐cell function and morphology in db/db mice. Biochem Biophys Res Commun 2006; 344: 1224–33
   PubMed Web of Science ®Google Scholar
• Chu K. Y., Leung P. S. Angiotensin II Type 1 receptor antagonism mediates uncoupling protein 2‐driven oxidative stress and ameliorates pancreatic islet beta‐cell function in young Type 2 diabetic mice. Antioxid Redox Signal 2007; 9: 869–78
   PubMedGoogle Scholar
• Huang Z., Jansson L., Sjoholm A. Pancreatic islet blood flow is selectively enhanced by captopril, irbesartan and pravastatin, and suppressed by palmitate. Biochem Biophys Res Commun 2006; 346: 26–32
   PubMed Web of Science ®Google Scholar
• Huang Z., Jansson L., Sjoholm A. Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats. Clin Sci 2007; 112: 69–76
   Web of Science ®Google Scholar
• Kansui Y., Fujii K., Goto K., Abe I., Iida M. Angiotensin II receptor antagonist improves age‐related endothelial dysfunction. J Hypertens 2002; 20: 439–46
   PubMed Web of Science ®Google Scholar
• Mizuno M., Sada T., Ikeda M., Fukuda N., Miyamoto M., Yanagisawa H., et al. Pharmacology of CS‐866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285: 181–8
   PubMed Web of Science ®Google Scholar
• Iwase M., Tashiro K., Uchizono Y., Goto D., Yoshinari M. Pancreatic islet blood flow in conscious rats during hyperglycemia and hypoglycemia. Am J Physiol 2001; 280: R1601–5
   Google Scholar
• Jansson L. Whole pancreatic blood flow and islet blood flow in hypovolemic hypotension in rats. Eur Surg Res 1992; 24: 291–7
   PubMedGoogle Scholar
• Jansson L. Evidence of an active regulation of pancreatic islet blood flow in rats. Studies in induced hypotension. Horm Metab Res 1993; 25: 651–2
   PubMedGoogle Scholar
• Lai E. Y., Jansson L., Patzak A., Persson A. E. Vascular reactivity in arterioles from normal and alloxan‐diabetic mice: studies on single perfused islets. Diabetes 2007; 56: 107–12
   PubMed Web of Science ®Google Scholar
• Carlsson P. O., Jansson L., Ostenson C. G., Kallskog O. Islet capillary blood pressure increase mediated by hyperglycemia in NIDDM GK rats. Diabetes 1997; 46: 947–52
   PubMed Web of Science ®Google Scholar
• A pathophysiological framework for the pathogenesis of diabetic microangiopathy. Diabetic angiopathy, J. E Tooke. Arnold, London 1999; 187–96
   Google Scholar
• Homo‐Delarche F., Calderari S., Irminger J. C., Gangnerau M. N., Coulaud J., Rickenbach K., et al. Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes 2006; 55: 625–33
   Google Scholar
• Li X., Zhang L., Meshinchi S., Dias‐Leme C., Raffin D., Johnson J. D., et al. Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes. Diabetes 2006; 55: 2965–73
   PubMed Web of Science ®Google Scholar
• Cooper M. E., Tikellis C., Thomas M. C. Preventing diabetes in patients with hypertension: one more reason to block the renin‐angiotensin system. J Hypertens 2006, Suppl 24: S57–63
   Google Scholar
• Leung P. S. Mechanisms of protective effects induced by blockade of the renin‐angiotensin system: novel role of the pancreatic islet angiotensin‐generating system in Type 2 diabetes. Diabet Med 2007; 24: 110–16
   PubMedGoogle Scholar
• Holst J. J., Orskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP‐1 agonism. Diabetes 2004; 53(Suppl 3)S197–204
   PubMedGoogle Scholar
• Svensson A. M., Ostenson C. G., Efendic S., Jansson L. Effects of glucagon‐like peptide‐1‐(7‐36)‐amide on pancreatic islet and intestinal blood perfusion in Wistar rats and diabetic GK rats. Clin Sci 2007; 112: 345–51
   Google Scholar
• Hostetter T. H., Rennke H. G., Brenner B. M. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375–80
   PubMed Web of Science ®Google Scholar